Company / Gross Margin
Corcept Therapeutics Incorporated Gross Margin History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
39.9%
FY2019
5-year range
-
FY2016-FY2019
Trend
-42.5%
vs FY2018
Sector context
#22 of 28
Health Care
What the data says
Corcept Therapeutics Incorporated's gross margin of 39.9% is lower than 79% of companies in the Health Care sector (FY2019). Improved from 16.9% to 39.9% over the past 2 years.
Based on SEC 10-K filings.
39.9% in FY2019 with a 3-year CAGR of -19.0%.
Improved from 16.9% to 39.9% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -19.0pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 28This company 39.9% Sector average 60.3%
▼
-33.8% below sector average
Key checks
Key Insights
- In FY2019, gross margin decreased 42.5% year-over-year.
- Currently 20.4pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | 39.9% | -42.5% |
| FY2018 | 69.5% | +310.3% |
| FY2017 | 16.9% | -71.3% |
| FY2016 | 59.0% | +202.6% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026